Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636842 · ClinicalTrials.gov registry record · Phase 1
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
A Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Alkermes.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 6
- Study locations
NCT02636842: Completed Phase 1 study of Schizophrenia and Schizoaffective Disorder, sponsored by Alkermes.
NCT02636842 is a Phase 1 study of Schizophrenia and Schizoaffective Disorder that has completed, run by Alkermes. The registered enrollment target is 47 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02636842, a Phase 1 study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
Conditions Studied
Interventions
- DRUG Aripiprazole Lauroxil
Study Locations (6)
California
- Alkermes Investigational Site - Cerritos
- Alkermes Investigational Site - Lemon Grove
- Alkermes Investigational Site - Oakland
Illinois
- Alkermes Investigational Site - Hoffman Estates
New Jersey
- Alkermes Investigational Site - Marlton
Texas
- Alkermes Investigative Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
What the finished NCT02636842 record still lists
NCT02636842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole Lauroxil is the first listed.
NCT02636842 lists 6 locations in 4 states (California, Illinois, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02636842 about?
NCT02636842 is a clinical study titled "A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder". The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder.
What is the current status of trial NCT02636842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2015-12. Estimated completion is 2016-06.
What conditions does trial NCT02636842 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
What interventions are being tested in trial NCT02636842?
The interventions under investigation include: Aripiprazole Lauroxil (DRUG).
Who is sponsoring clinical trial NCT02636842?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02636842 being conducted?
This trial has 6 study locations across California, Illinois, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02636842's enrollment target sits among peer trials
47 223rd of 315 higher than 91 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia